IDO1 and metastatic melanoma: In metastatic melanoma patients, the patients with a short survival (mean: 8 months) had all an IDO-expressing tumor, as detected by immunochemistry, whereas only 20% of the long survivors (mean: 262 months) had an IDO-positive tumor [304].